Patent Settlements DO Help Patients
Wonder why the generic industry opposes a bill purported to help the generic industry?
Rich’s Generic Story: No Sweat
When Rich noticed himself sweating excessively, he made a doctor’s appointment—something he admits he doesn’t do as often as he should. The diagnosis was a common thyroid condition.The prescription: a generic medication.
HHS Proposal Will Help America’s Patients Realize the Full Value of Their Generics and Biosimilars
America’s patients continue to cite high prescription drug costs as a major issue, and the Trump administration has responded with a series of proposals to reduce out-of-pocket costs for patients and overall spending on high-priced brand drugs.
Access! New Orleans Style: An Industry Steps Up
AAM’s annual conference offered familiar benefits to attendees as well as new, exciting experiences that encapsulated an industry rising to the challenges of a shifting health care landscape. New Orleans flavors and sounds permeated Access! 2019.
AAM Welcomes Re-Introduction of the PACED Act
WASHINGTON, DC (February 13, 2019) — With everyone from patients to the President demanding action on drug pricing, AAM welcomes the re-introduction of the Preserving Access to Cost Effective Drugs (PACED) Act.
Generic Medicines Save Money for Patients and Taxpayers
AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our core mission is to improve the lives of patients by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of prescription medicines in the United States every year.
Key Points:
Alex Azar to Speak at Access! 2019
The morning after the President's State of the Union address, Health and Human Services Secretary Alex Azar will livestream from AAM's Annual Meeting in New Orleans: Access! 2019.
Tune in on Wednesday, February 6 at 11:15 CST to hear the Secretary detail the Administration's plans to enhance competition to lower drug prices for American patients.
Rate-Setting Bills
AAM’s core mission is to improve patients’ lives by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of prescription medicine in the US annually.
Key Points:
Drug Price Transparency Bills
AAM’s core mission is to improve patients’ lives by advancing timely access to affordable, FDA-approved generic and biosimilar medicines. AAM is the nation’s leading trade association for manufacturers and distributors of generic and biosimilar prescription medicines. Our members provide more than 36,000 jobs at nearly 150 facilities, and manufacture more than 61 billion doses of prescription medicine in the US annually.
Key Points:
AAM Statement on Trump Administration’s Proposal to Lower Drug Costs by Targeting Backdoor Rebates
WASHINGTON DC (February 1, 2019) – “AAM applauds the Administration’s efforts to reduce high brand drug costs for patients. Too often, brand drug companies are using rebate traps to block patient access to more affordable generic or biosimilar medicines. We look forward to reviewing the proposal and working with the Administration to ensure that America's patients have access to more affordable generic and biosimilar therapies.”